Curemark LLC, a Rye, NY-based drug research and development company, closed an $18.5m in equity financing.
The round was led by a European institutional investor.
The company intends to use the funds for the completion and filing requirements for its New Drug Application (NDA) for CM-AT, its autism treatment, and the development of the other therapies in its pipeline.
Led by Dr. Joan Fallon, founder and CEO, Curemark focuses on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies.
FinSMEs
08/10/2013